Bio-Techne Corporation

TECH · NASDAQ · USD

Historical Earnings

Quarter	Reported	EPS est	EPS act	Surprise	Rev est	Rev act	Surprise	Reaction
Q4 2026	Aug 12, 2026	0.52	0.52	+0.2%	$314.6M	$321.2M	+2.1%	−0.08%
Q3 2026	May 6, 2026	0.55	0.53	−3.6%	$316.1M	$311.4M	−1.5%	+7.39%
Q2 2026	Feb 4, 2026	0.43	0.46	+7.0%	$290.5M	$295.9M	+1.9%	−4.09%
Q1 2026	Nov 5, 2025	0.42	0.42	−0.3%	$291.3M	$286.6M	−1.6%	−2.94%
Q4 2025	Aug 6, 2025	0.50	0.53	+6.0%	$314.6M	$317.0M	+0.7%	+0.56%
Q3 2025	May 7, 2025	0.51	0.56	+9.8%	$317.2M	$316.2M	−0.3%	+2.11%
Q2 2025	Feb 5, 2025	0.39	0.42	+7.7%	$285.8M	$297.0M	+3.9%	−0.32%
Q1 2025	Oct 30, 2024	0.38	0.42	+10.5%	$280.3M	$289.5M	+3.3%	−2.99%

Detailed View

Q1 2027Nov 4, 2026Q4 2026Aug 12, 2026−0.08%Q3 2026May 6, 2026+7.39%Q2 2026Feb 4, 2026−4.09%Q1 2026Nov 5, 2025−2.94%Q4 2025Aug 6, 2025+0.56%Q3 2025May 7, 2025+2.11%Q2 2025Feb 5, 2025−0.32%Q1 2025Oct 30, 2024−2.99%Q4 2024Aug 7, 2024Q3 2024May 1, 2024Q2 2024Feb 1, 2024

2026 Q4 Metrics

Metric	Estimate	Actual	Surprise	Y/Y
Revenue	$314.6M	$321.2M	Beat +2.09%	+1.3%
EPS	0.52	0.52	Match +0.19%	−1.9%
Diluted EPS (GAAP)	—	0.36	—	+427.3%

Documents

8-K — Q4 2026
8-K · Sep 23, 2026 · sec.gov
8-K — Q4 2026
8-K · Sep 14, 2026 · sec.gov
10-K — Q4 2026
10-K · Aug 24, 2026 · sec.gov
8-K — Q4 2026
8-K · Aug 12, 2026 · sec.gov

Analyst consensus

Hold26 analysts

Bearish · 0 · Hold · 14 · Bullish · 12

Earnings history

	EPS	Estimate
Q1 2025	$0.42	$0.38	Beat
Q2 2025	$0.42	$0.39	Beat
Q3 2025	$0.56	$0.51	Beat
Q4 2025	$0.53	$0.50	Beat
Q1 2026	$0.42	$0.42	Match
Q2 2026	$0.46	$0.43	Beat
Q3 2026	$0.53	$0.55	Miss
Q4 2026	$0.52	$0.52	Match

Peers

Company overview

IPO dateFeb 9, 1989

CEOKim Kelderman

Employees3,000

SectorHealthcare

IndustryBiotechnology

CountryUS

ExchangeNASDAQ

Websitewww.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.